Methenamine Hippurate for Recurrent UTI Prevention

Methenamine hippurate is one of the oldest urinary antiseptics still in clinical use, and recent research has pushed it back into the spotlight as a non-antibiotic option for preventing recurrent urinary tract infections. It works by breaking down in acidic urine to release formaldehyde, which kills bacteria in the bladder without operating like a conventional antibiotic. For women who deal with repeated UTIs, the drug offers a way to reduce infections while sidestepping much of the antibiotic resistance that comes with long-term preventive antibiotic use.

How Methenamine Hippurate Works

The drug is a combination of two components. Methenamine is the active core, a compound that decomposes in acidic conditions to produce formaldehyde. Hippuric acid is the other half, and it serves a dual purpose: it helps the drug dissolve and pass through the kidneys efficiently, and it contributes to acidifying the urine, which is exactly the environment methenamine needs to do its job.¹ Once the formaldehyde is released in the bladder, it acts as a broad-spectrum antiseptic, damaging bacterial proteins and DNA indiscriminately rather than targeting a specific metabolic pathway the way antibiotics do.

This indiscriminate mechanism is why the drug has long been assumed to be resistance-proof. Since formaldehyde is a general-purpose chemical killer and not a precision-targeted antibiotic, bacteria were not thought to develop resistance to it in the way they do to drugs like trimethoprim or nitrofurantoin.² That assumption, as we’ll see, has recently come under closer scrutiny.

Preventing Recurrent UTIs in Women

The strongest evidence for methenamine hippurate centers on women who experience recurrent uncomplicated UTIs, typically defined as two or more infections in six months or three or more in a year. An updated meta-analysis pooling data from multiple randomized controlled trials concluded that methenamine hippurate is an effective and safe prophylactic option for preventing recurrent UTIs in adult women.³

A recent placebo-controlled trial specifically in older women with recurrent UTIs found that methenamine hippurate reduced infection frequency by roughly a quarter compared to placebo.⁴ A 25% reduction may not sound dramatic on its own, but for someone dealing with four or five infections a year, dropping one or two of those episodes translates into meaningfully fewer rounds of antibiotics, fewer urgent care visits, and less disruption to daily life.

How It Stacks Up Against Preventive Antibiotics

For decades, the standard approach to recurrent UTIs has been low-dose daily antibiotics, commonly nitrofurantoin or trimethoprim, taken for months at a stretch. The obvious downside is that prolonged antibiotic use breeds resistant bacteria. A major UK-based trial (known as ALTAR) directly compared methenamine hippurate to daily antibiotic prophylaxis in women with recurrent UTIs and found that methenamine hippurate was non-inferior, meaning it performed within an acceptable margin of the antibiotic regimen for preventing infections.⁵ The difference in UTI rates between the two groups did not exceed one infection per person-year, the threshold the trial had pre-defined as acceptable.

A separate head-to-head comparison of methenamine hippurate versus low-dose nitrofurantoin reached a similar conclusion: the drug was non-inferior for UTI prevention and came with fewer adverse events and less antibiotic resistance.⁶ The practical takeaway is that if you’re someone whose doctor has suggested long-term preventive antibiotics, methenamine hippurate offers roughly comparable protection without exposing you to the same resistance risks.

The Antibiotic Resistance Advantage

Resistance is where methenamine hippurate has its most compelling edge. In the ALTAR trial, about 72% of women taking daily antibiotics showed antibiotic-resistant E. coli on perineal swabs during treatment, compared to about 56% in the methenamine hippurate group.⁷ The antibiotic group also had higher rates of E. coli resistant to trimethoprim, co-trimoxazole, and cephalosporins. This matters because those are the very antibiotics most commonly used to treat UTIs when they do occur. If your preventive regimen breeds bacteria resistant to treatment antibiotics, the next acute infection becomes harder to treat.

This resistance benefit is a large part of why clinical guidelines and infectious-disease experts have renewed their interest in methenamine hippurate. Commentary on the ALTAR trial argued that incorporating methenamine hippurate into UK and European guidelines could help combat the growing threat of antimicrobial resistance.⁸ In the United States, the updated AUA/CUA/SUFU guideline now lists methenamine hippurate as an option clinicians may offer for UTI prophylaxis, though with a conditional recommendation reflecting the still-evolving evidence base.⁹

Cost and Quality of Life

Switching from antibiotics to methenamine hippurate also appears to be economically sensible. A cost-effectiveness analysis conducted alongside the ALTAR trial found that methenamine hippurate was, on average, slightly less expensive than antibiotic prophylaxis and slightly more effective in terms of quality-adjusted life-years gained.¹⁰ The probability of methenamine hippurate being considered cost-effective ranged from about 51% to 67% across different willingness-to-pay thresholds. Those numbers become more favorable when the broader societal costs of antibiotic resistance are factored in, since reduced resistance means fewer treatment failures, fewer hospitalizations for resistant infections, and lower healthcare spending down the line.

That said, the cost-effectiveness finding was described as subject to uncertainty and not fully consistent over longer follow-up periods.¹¹ In other words, the economic case is promising but not iron-clad. The cleaner argument remains the resistance one: even if the two drugs cost the same, one of them erodes your future treatment options and the other largely doesn’t.

Why Urine pH Matters So Much

Methenamine hippurate’s effectiveness hinges on urine acidity. The drug only releases formaldehyde in a sufficiently acidic environment. If your urine stays too alkaline, the chemical reaction slows or stalls, and the drug simply passes through without doing much. This pH dependency has real-world consequences.

A prospective pilot study in postmenopausal women with recurrent UTIs confirmed that durable levels of both methenamine and formaldehyde could be detected in urine when the urinary pH was kept low.¹² The study showed clinical efficacy alongside confirmed formaldehyde presence. Some clinicians suggest pairing methenamine hippurate with vitamin C or cranberry products to help maintain acidic urine, though the evidence for these adjuncts is mixed. The hippuric acid component of the drug does contribute some acidification on its own, but it may not always be enough.

The pH issue is also why methenamine hippurate has limited usefulness against certain bacteria. Proteus species, a group of bacteria that cause UTIs and are especially common in people with structural urinary abnormalities, produce an enzyme called urease that breaks down urea into ammonia, actively alkalinizing the urine. Research has noted that methenamine’s effectiveness against Proteus infections is limited precisely because of this urine alkalinity problem.¹³ If your recurrent UTIs are caused by Proteus rather than E. coli, methenamine hippurate may not be the right choice.

Catheterized Patients and Other Weak Spots

One area where methenamine hippurate has consistently underperformed expectations is in people with urinary catheters. Catheters introduce bacteria directly into the bladder on a near-continuous basis and create biofilms that are notoriously difficult to disrupt. Reviews of the evidence have found that studies did not show reliable benefit of methenamine therapy in suppressing catheter-associated bacteriuria.¹⁴ The likely explanation is that the formaldehyde concentrations achievable in urine simply can’t overcome the bacterial load and biofilm associated with an indwelling catheter.

People with severe kidney impairment also need to avoid the drug. Manufacturers advise against methenamine use in patients with a glomerular filtration rate below 10 mL/min because of the risk of toxic accumulation.¹⁵ For people with moderate kidney problems, the drug is generally still considered safe, but dosing should be discussed with a doctor. In that same study of renal transplant recipients, methenamine hippurate was used without notable safety signals, though the authors were careful to exclude anyone with severely reduced kidney function.

New Questions About Formaldehyde Resistance

One of methenamine hippurate’s selling points has always been the claim that resistance can’t develop because formaldehyde isn’t a targeted antibiotic. A 2024 study in PLOS Pathogens called that assumption into question. Researchers analyzed urine samples from the ALTAR trial and detected formaldehyde in 85% of samples from participants taking methenamine hippurate. However, when they measured the actual formaldehyde concentration using more precise methods, they found levels above 0.7 µM in only about half of the methenamine users.¹⁶

More striking, the researchers identified significant changes in urine composition among methenamine users, including elevated levels of formate, a byproduct of formaldehyde metabolism. The study raised the possibility that bacteria exposed to sub-lethal concentrations of formaldehyde could develop tolerance mechanisms, though this finding is still early-stage. It doesn’t mean methenamine hippurate is ineffective, but it challenges the reassuring narrative that resistance is categorically impossible. This is the kind of question that will likely attract more research in the coming years, especially as prescribing increases.

Side Effects and Tolerability

Methenamine hippurate is generally well tolerated. The most commonly reported side effects are gastrointestinal: nausea, stomach upset, and occasionally diarrhea. These tend to be mild and often resolve on their own. Skin rashes have been reported but are uncommon. The ALTAR trial and the more recent ImpresU trial both described the side effect profile as mild, which is one of the advantages cited in the ImpresU trial’s conclusion alongside the low potential for resistance.¹⁷

Compared to low-dose antibiotics, the tolerability edge is real. Nitrofurantoin, one of the most commonly used prophylactic antibiotics for recurrent UTIs, can cause lung and liver toxicity with prolonged use, and trimethoprim can cause rashes and blood count changes. Methenamine hippurate has no equivalent organ-toxicity concerns at standard doses. The usual regimen is one gram taken twice daily, though some clinicians adjust this based on individual factors.

Where It Fits in the UTI Prevention Toolkit

Recurrent UTIs are frustratingly common, affecting roughly a quarter to a third of women who have an initial infection. The prevention toolkit has historically been dominated by behavioral changes (hydration, post-intercourse voiding) and long-term low-dose antibiotics. Methenamine hippurate occupies a middle ground: more potent than lifestyle adjustments alone, less risky than continuous antibiotics. The AUA/CUA/SUFU guideline’s conditional recommendation reflects this positioning. The drug is an option, not necessarily the first-line standard, but increasingly seen as appropriate especially when antibiotic stewardship is a concern.¹⁸

Other non-antibiotic options exist, including cranberry supplements, D-mannose, and vaginal estrogen for postmenopausal women. Methenamine hippurate has a stronger clinical-trial evidence base than most of these alternatives, particularly after the ALTAR trial and subsequent meta-analyses. But it works best as part of a broader strategy rather than a standalone solution. Keeping urine acidic, staying well hydrated, and addressing any underlying anatomical or hormonal factors all contribute to reducing UTI recurrence.

Methenamine Hippurate and Kidney Stones

One concern that occasionally comes up is whether long-term methenamine hippurate use could increase the risk of kidney stones. The hippuric acid component acidifies urine, and highly acidic urine can in some circumstances promote certain types of stone formation, particularly uric acid stones. Some older literature explored this question, and the general consensus among urologists is that at standard doses in people without a pre-existing stone history, the risk is low. However, if you have a personal history of uric acid stones or gout, it’s worth discussing this with your doctor before starting the drug. Adequate fluid intake, which is already recommended for UTI prevention, also helps mitigate stone risk by diluting urine.

Renal Transplant Recipients

People who have received kidney transplants are at high risk for UTIs because the immunosuppressive medications they take to prevent organ rejection also weaken their defenses against infection. Antibiotics are the go-to prevention strategy, but the resistance concerns are amplified in this population since resistant infections in an immunocompromised person are especially dangerous. A retrospective study at a single center found that methenamine hippurate could be used safely in adult renal transplant recipients, provided their kidney function was adequate.¹⁹ This is a niche population, but it illustrates the broader trend of clinicians looking for ways to prevent UTIs without adding to the antibiotic resistance burden in vulnerable patients.

Lab Test Interference

One practical detail that rarely makes it into patient discussions is that methenamine hippurate can interfere with certain urinalysis results. The formaldehyde released into urine can react with some of the chemical reagents used in dipstick tests, potentially producing misleading results. In the PLOS Pathogens analysis of ALTAR trial urines, researchers found that methenamine use significantly altered urine composition beyond just the presence of formaldehyde, including elevated formate levels.²⁰ If you’re taking methenamine hippurate and need a urine test for any reason, let the lab or your doctor know. This is particularly relevant for the urine culture tests used to diagnose UTIs, since formaldehyde in the sample could suppress bacterial growth in the culture dish and make an active infection look negative.